Impact of Lactocaseibacillus (Lactobacillus) paracasei sup. paracasei TISTR 2593 Probiotic Supplementation on the Gut Microbiome of Hypercholesterolemia Patients: A Randomized Controlled Trial.

Autor: Nuankham, Kamonsri, Sitdhipol, Jaruwan, Chonpathompikunlert, Pennapa, Khongrum, Jurairat, Kittichaiworakul, Romteera, Noisagul, Pitiporn, Thongkumkoon, Patcharawadee, Kampoun, Tanyaluck, Dissook, Sivamoke
Zdroj: Nutrients; Sep2024, Vol. 16 Issue 17, p2916, 11p
Abstrakt: Probiotics have shown potential in managing hypercholesterolemia and related metabolic conditions. This study evaluated the effects of Lactocaseibacillus (Lactobacillus) paracasei sup. paracasei TISTR 2593 on the gut microbiome and metabolic health in patients with hypercholesterolemia, and was registered in the Thai Clinical Trial Registry (TCTR 20220917002). In a randomized, double-blind, placebo-controlled trial, 22 hypercholesterolemic participants received either the probiotic or a placebo daily for 90 days. Fecal samples collected before and after the intervention revealed significant microbiome changes, including a decrease in Subdoligranulum, linked to rheumatoid arthritis, and an increase in Flavonifractor, known for its anti-inflammatory properties. Additionally, the probiotic group exhibited a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels. These findings suggest that L. paracasei TISTR 2593 can modulate the gut microbiome and improve metabolic health, warranting further investigation into its mechanisms and long-term benefits. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index